Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
January 08, 2024 07:00 ET
|
Tourmaline Bio, Inc.
Tourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 weeks as first-line treatment for TED, with topline data expected in 2026 ...
Tourmaline Bio added to the NASDAQ Biotechnology Index
December 15, 2023 16:00 ET
|
Tourmaline Bio, Inc.
NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
December 14, 2023 07:30 ET
|
Tourmaline Bio, Inc.
NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
Tourmaline Bio to Present at Upcoming Investor Conferences
November 01, 2023 08:00 ET
|
Tourmaline Bio, Inc.
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of...
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
October 19, 2023 17:37 ET
|
Tourmaline Bio, Inc.
Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases ...
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
October 17, 2023 17:47 ET
|
Talaris Therapeutics, Inc.
Combined Company to Trade on Nasdaq Under Ticker “TRML”Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq:...
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio
October 06, 2023 17:09 ET
|
Talaris Therapeutics, Inc.
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE)...
Tourmaline Bio Appoints Gerhard Hagn as SVP, Head of Commercial and Business Development
September 20, 2023 08:00 ET
|
Tourmaline Bio, Inc.
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of...
Tourmaline Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TOUR006, an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED)
August 28, 2023 07:30 ET
|
Tourmaline Bio, Inc.
NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of...
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
June 22, 2023 07:30 ET
|
Talaris Therapeutics, Inc.
Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic...